Predicting Response to Capecitabine in Women With Metastatic Breast Cancer

• Status: Completed
• Trial end date: 2011-02-01
• Target enrollment: 0
• Participant gender: Female

Summary

RATIONALE: Identifying genes that increase a person's susceptibility to side effects caused by capecitabine may help doctors plan better treatment.

PURPOSE: This clinical trial is studying blood samples in predicting response to capecitabine in women with metastatic breast cancer.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Antoine Lacassagne
• Treatments: Capecitabine

Criteria

DISEASE CHARACTERISTICS:

• Radiologically (by scintography) or histologically confirmed metastatic breast cancer

• At least 1 measurable or evaluable target lesion

• Receiving capecitabine as monotherapy or with targeted antiangiogenic therapies (e.g., bevacizumab or trastuzumab)

• No uncontrolled brain metastases

• Hormone receptor status not specified

PATIENT CHARACTERISTICS:

• Menopausal status not specified

• Life expectancy ≥ 3 months

• Fertile patients must use effective contraception

• No chronic uncontrolled illness

• No congestive heart failure

• No peripheral venous disease

• No severe uncontrolled infection

• No hypoxemic respiratory failure

• No prior primary cancer except for basal cell carcinoma of the skin

• No psychologic disorder

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• No capecitabine co-administered with chemotherapy